Résumé
Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
| langue originale | Anglais |
|---|---|
| Pages (de - à) | 38-42 |
| Nombre de pages | 5 |
| journal | British Journal of Cancer |
| Volume | 118 |
| Numéro de publication | 1 |
| Les DOIs | |
| état | Publié - 1 janv. 2018 |
| Modification externe | Oui |
Accès au document
Autres fichiers et liens
Contient cette citation
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Dans: British Journal of Cancer, Vol 118, Numéro 1, 01.01.2018, p. 38-42.
Résultats de recherche: Contribution à un journal › Article › Revue par des pairs
TY - JOUR
T1 - Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC
AU - Gadgeel, Shirish
AU - Shaw, Alice T.
AU - Barlesi, Fabrice
AU - Crinò, Lucio
AU - Yang, James Chih Hsin
AU - Dingemans, Anne Marie C.
AU - Kim, Dong Wan
AU - De Marinis, Filippo
AU - Schulz, Mathias
AU - Liu, Shiyao
AU - Gupta, Ravindra
AU - Kotb, Ahmed
AU - Ou, Sai Hong Ignatius
N1 - Funding Information: SG has participated in advisory boards for Genentech/Roche, Ariad, Pfizer, and Bristol-Myers Squibb, and received honoraria for non-branded presentations for Genentech/Roche; ATS has participated in advisory boards for Pfizer, Novartis, Roche/Genentech, Ariad, Blueprint Medicines, Loxo, and EMD Serono, and received honoraria for non-branded presentations for Pfizer, Novartis, Genentech/Roche, Ignyta, Taiho and Foundation Medicine; FB has participated in advisory boards for Genentech/Roche, Novartis, and Pfizer, and received honoraria for non-branded presentations for Genentech/Roche and Novartis; LC has received honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, and Pfizer; JC-HY has participated in compensated advisory boards for Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genen-tech/Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Merrimack, Yuhan Pharmaceuticals, Bristol-Myers Squibb, and Ono Pharmaceutical, and in an uncompensated advisory board for AstraZeneca; A-MCD has participated in advisory boards for Genentech/Roche, Pfizer, Eli Lilly, Clovis, and MSD, and received honoraria for non-branded presentations for Genentech/Roche and AstraZeneca (paid to her institute); D-WK has no conflict of interest to disclose; FdM has participated in advisory boards for Genentech/Roche, Boehringer, and Novartis, and received honoraria for non-branded presentations from Genentech/Roche, AstraZeneca, Bristol-Mayer Squibb, and Pfizer; MS is an employee of Genentech and owns Roche stocks; SL and RG are employees of Genentech and own shares in the company; AK is an employee of F. Hoffmann-La Roche Ltd and owns shares in the company; S-HIO has acted in a consulting or advisory role to ARIAD, AstraZeneca, Boehringer Ingelheim, Novartis, and Roche, and participated in Speaker Bureaus for AstraZeneca, Boehringer Ingelheim, and Roche/Genentech. Funding Information: We thank the patients, their families, and the participating centres for both studies. Third-party medical writing assistance, under the direction of the authors, was provided by Fiona Fernando of Gardiner-Caldwell Communications and funded by F. Hoffmann-La Roche Ltd.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
AB - Background:We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS disease.Methods:Patients with crizotinib-pretreated locally advanced or metastatic disease received alectinib 600 mg orally twice daily in two phase II trials. All patients underwent baseline imaging and regular centrally reviewed scans.Results:At 24 months, the CIR for CNS progression was lower in patients without vs with baseline CNS metastases (8.0 vs 43.9%). Patients with baseline CNS disease and prior radiotherapy had a higher CIR of CNS progression than radiotherapy-naive patients (50.5 vs 27.4%) and a lower CIR of non-CNS progression (25.8 vs 42.5%). Adverse events leading to withdrawal occurred in 5.9% and 6.7% of patients with and without baseline CNS metastases, respectively.Conclusions:This analysis indicates a potential role for alectinib in controlling and preventing CNS metastases.
KW - ALK positive
KW - alectinib
KW - central nervous system
KW - cumulative incidence rates
KW - disease progression
KW - non-small-cell lung cancer
KW - phase II
UR - http://www.scopus.com/inward/record.url?scp=85040316540&partnerID=8YFLogxK
U2 - 10.1038/bjc.2017.395
DO - 10.1038/bjc.2017.395
M3 - Article
C2 - 29149104
AN - SCOPUS:85040316540
SN - 0007-0920
VL - 118
SP - 38
EP - 42
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -